Table 6.
Comparison of characteristics of patient with late recurrence according to response to the first-line therapy.
| Short PFS group | Long PFS group | ||
|---|---|---|---|
| n = 24 | n = 24 | P value | |
| Age, years | 54 (35–80) | 53 (36–75) | 0.41 |
| Menopausal status | 1.00 | ||
| Premenopausal | 7 (46.7 %) | 16 (48.5 %) | |
| Postmenopausal | 8(53.3) | 17 (51.5 %) | |
| ER (%) | 1.00 | ||
| <10 | 0 (0 %) | 1 (3.0 %) | |
| ≥10 | 15 (100 %) | 32 (97.0 %) | |
| PR (%) | 0.66 | ||
| <10 | 3 (20 %) | 3 (9.1 %) | |
| ≥10 | 12 (80 %) | 30 (90.9 %) | |
| Number of distant metastasis | 1.00 | ||
| Single | 12 (80 %) | 25 (75.8 %) | |
| Multiple | 3 (20 %) | 8 (24.2 %) | |
| Site of distant metastasis | 0.46 | ||
| Bone | 7 (46.6 %) | 17 (51.5 %) | |
| Lung | 6 (40.0 %) | 16 (48.4 %) | |
| Liver | 1 (6.6 %) | 6 (18.1 %) | |
| Other | 1 (6.6 %) | 1 (3.0) | |
| Distant disease-free survival | 0.036 | ||
| <7 years | 9 (37.5 %) | 2 (8.3 %) | |
| ≥7 years | 15 (62.5 %) | 22 (91.7 %) | |
| First-line treatment | 0.724 | ||
| Chemotherapy | 4 (17.4 %) | 6 (25.0 %) | |
| Endocrine therapy | 18 (78.3 %) | 18 (75.0 %) | |
| Radiation therapy | 1 (4.3 %) | 0 (0 %) | |
| Duration of HT | 6.5 months (0–41) | 40 months (14–93) | <0.001 |
| PFS | 6 months (3–11) | 25 months (14–84) | <0.001 |
PFS. Progression-free survival; ER, estrogen receptor; PR, progesterone receptor.